DiscoverCME in Minutes: Education in Primary CareVlad Ratziu, MD, PhD - Bridging Disciplines to Advance Care in MASH: Exploring GLP-1 RAs for Obesity-Related Liver Disease
Vlad Ratziu, MD, PhD - Bridging Disciplines to Advance Care in MASH: Exploring GLP-1 RAs for Obesity-Related Liver Disease

Vlad Ratziu, MD, PhD - Bridging Disciplines to Advance Care in MASH: Exploring GLP-1 RAs for Obesity-Related Liver Disease

Update: 2025-09-24
Share

Description

Please visit answersincme.com/WTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hepatology and endocrinology discuss the impact of obesity on liver disease progression, current and emerging GLP-1 receptor agonist therapies, and strategies to optimize clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Upon completion of this activity, participants should be better able to: Identify how obesity impacts metabolic dysfunction–associated steatohepatitis (MASH) progression and liver health; Review current and emerging glucagon-like peptide-1 (GLP-1) receptor agonist (RA)–based therapies for the treatment of MASH; and Outline approaches to optimize patient outcomes in obesity-related liver disease.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Vlad Ratziu, MD, PhD - Bridging Disciplines to Advance Care in MASH: Exploring GLP-1 RAs for Obesity-Related Liver Disease

Vlad Ratziu, MD, PhD - Bridging Disciplines to Advance Care in MASH: Exploring GLP-1 RAs for Obesity-Related Liver Disease

Answers in CME